Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fees Should Be A Last Resort For NICE Funding, Says UK Medtechs

Executive Summary

UK industry has given its rationale for opposing health technology assessment fees from NICE, but suggests that it might be prepared to discuss the general theme of NICE funding if the conditions were right.

Advertisement

Related Content

UK Looks To Model New Medtech Strategy On US Successes
UK Accelerated Access Review Can Create A Post-Brexit 'Medtech Powerhouse'
UK Diagnostic Fret Over Loss of Support In Evidence Centers Restructure
Medtech Worried After UK HTA Body Moots Pharma Guidance Fees
UK Accelerated Access Proposals Due Out Soon

Topics

Advertisement
UsernamePublicRestriction

Register

MT103934

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel